Clinical Trial Update: JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update indicates JY025 is being studied as first-line treatment for EGFR-mutated non-small cell lung cancer in Phase 2 and Phase 3 trials; effica…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• JY025

Snippet

Sponsor: Beijing Dongfang Biotech Co., Ltd. | Conditions: NSCLC | Phase 2, Phase 3 | Status: UNKNOWN